Lundbeck Canada is a subsidiary of H. Lundbeck A/S, an international research-based pharmaceutical company focused on brain diseases and oncology. Based in Montreal, Lundbeck Canada has been active in the Canadian pharmaceutical industry for almost two decades, marketing products for the treatment of depression, anxiety, Alzheimer’s disease, schizophrenia, bipolar disorders, chronic lymphocytic leukemia, non-Hodgkin lymphoma, and acute promyelocytic leukemia.
Through research, development, education, and partnerships with other companies and patient organizations, Lundbeck employees are improving the quality of life for people living with brain diseases and cancer.
Contact:
Address: 2600 Alfred-Nobel boulevard | Suite 400 | Saint-Laurent | H4S 0A9 | Montréal Québec
Tel.: +1 514 844 8515
Website: http://www.lundbeck.com/ca/en
Sylvie Pilon, VP and GM at Lundbeck Canada, shares the highlights of her first year leading the Canadian affiliate; the challenges associated with Canada’s complex market access environment, particularly for…
The head of Lundbeck in Canada talks about the stigma of mental illness that still exists in the country today, and how CNS companies like Lundbeck are working with stakeholders…
Drs Neil Cashman and Larry Altstiel of ProMIS Neurosciences weigh in on recent progress towards an effective therapy for Alzheimer’s disease, potentially representing a break from three decades of scientific…
Some of the top stories coming out of Canadian healthcare and life sciences, including a new GSK flu vaccine deal, Amylyx Pharmaceuticals’ first approval for an ALS drug, and the…
In April, the Canadian Ministry of Health announced the government would not be proceeding with certain proposed amendments to the Patented Medicines Regulations which govern the Patented Medicine Prices Review…
In conversation in the October edition of DIA’s Global Forum magazine, Canadian Agency for Drugs and Technologies in Health (CADTH) CEO Suzanne McGurn highlights how the work of HTA bodies…
Writing in the September edition of DIA’s Global Forum magazine, Dr Judith Glennie examines the specific steps that have been taken in the journey towards a National Pharmacare program in…
Writing in the March edition of DIA’s Global Forum magazine, Judith Glennie examines the findings of Health Canada’s consultation with Canadians on what a national strategy for high-cost rare disease…
Clint Sharples, CEO of Heritage Cannabis, gives a potted history of the medical cannabis industry in Canada, its current legal status, provincial variations in patient registrations, financial performance, the impact…
As the only country in the world to boast a universal healthcare system that does not cover prescription drugs, Canada has been struggling with the concept of ‘national pharmacare’ for…
The latest news from Canadian pharma including deals for J&J’s and Novavax’s COVID-19 vaccines, an abrupt end to Canada’s participation in CanSino Biologics’ clinical trials the country’s first medical cannabis…
Pushback from drug companies on Canada’s newest drug pricing regulations has led the country’s regulatory body to reconsider their implementation. Companies cite the push for cost-effectiveness as a reason for…
Dr Neil Cashman looks at the potential impact of US FDA approval for Biogen’s aducanumab on the search for Alzheimer’s Disease (AD) treatments, and how Canada is playing a leading…
John L. Wallace of Antibe Therapeutics highlights how Canadian innovation stands to put the country at the forefront of the next wave of global biopharmaceutical R&D. BlueRock Therapeutics, a promising…
See our Cookie Privacy Policy Here
